Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PF-07820435 alone and with sasanlimab in advanced solid tumors
jRCT2031230747Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of PF-07820435 and sasanlimab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and transitional cell carcinoma (TCC) (4 arms), sponsored by Pfizer. Primary endpoints: Number of patients with dose limiting toxicities in dose escalation, Number of patients with adverse events and 2 more. Started Apr 2024; status: completed.
02
Drugs
PF-07820435sasanlimab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on jRCT2031230747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230747.